Back to Search
JOSEPH ERON, MD
MD
Infectious Disease Physician
NPI: 1598838336IndividualAccepts Medicare
Specialties, Licenses & Credentials
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
35891(NC)
Education
HARVARD MEDICAL SCHOOL
Class of 1984
Research & Publications (20)
Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy.
PMID 19307363·Antimicrob Agents Chemother·2009
3-trial
Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions.
PMID 18447612·J Infect Dis·2008
6-review
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
PMID 16890834·Lancet·2006
4-observational
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.
PMID 14722892·J Infect Dis·2004
3-trial
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
PMID 14999611·J Infect Dis·2004
3-trial
Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.
PMID 15577413·J Acquir Immune Defic Syndr·2004
3-trial
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.
PMID 11391165·J Acquir Immune Defic Syndr·2001
3-trial
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
PMID 10983647·AIDS·2000
3-trial
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
PMID 10783117·J Infect Dis·2000
3-trial
Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
PMID 10807190·AIDS·2000
3-trial
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.
PMID 19582166·PLoS Med·2009
8-other
The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.
PMID 19417582·AIDS·2009
8-other
Sexually transmitted infections among patients with acute HIV in North Carolina.
PMID 19387421·Sex Transm Dis·2009
8-other
A novel codon insert in protease of clade B HIV type 1.
PMID 19397401·AIDS Res Hum Retroviruses·2009
8-other
Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, Malawi.
PMID 19397436·AIDS Educ Prev·2009
8-other
Adaptation of orientation of central otolith-only neurons.
PMID 19645928·Ann N Y Acad Sci·2009
7-preclinical
Effect of early versus deferred antiretroviral therapy for HIV on survival.
PMID 19339714·N Engl J Med·2009
4-observational
Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies.
PMID 19555288·Clin Infect Dis·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 101 MANNING DR
CHAPEL HILL, NC 27599 - Phone
- (919) 966-4996
Quick Facts
- NPI
- 1598838336
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile